DiaMedica Therapeutics
DMAC
17 hedge funds and large institutions have $1.98M invested in DiaMedica Therapeutics in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
6% more funds holding
Funds holding: 16 → 17 (+1)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
2.76% less ownership
Funds ownership: 10.73% → 7.97% (-2.8%)
69% less capital invested
Capital invested by funds: $6.37M → $1.98M (-$4.39M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$151K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$49.8K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$44.3K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$42.9K |
| 5 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$30K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WC
Wexford Capital
West Palm Beach,
Florida
|
-$1.01M |
| 2 |
Goldman Sachs
New York
|
-$253K |
| 3 |
EVC
Eidelman Virant Capital
Saint Louis,
Missouri
|
-$173K |
| 4 |
Millennium Management
New York
|
-$91.9K |
| 5 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$8.86K |
DMAC Hedge Fund Activity: Q3 2019 in Review
17 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q3 2019, worth a combined $1.98M — down 69% from $6.37M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new DMAC positions and 3 closed out — a net gain of 1 holder — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $151K. The largest seller was Wexford Capital, cutting an estimated $1.01M.
- 17 institutional investors held DiaMedica Therapeutics (DMAC) as of Q3 2019, up from 16 in Q2 2019.
- Funds reported $1.98M of DiaMedica Therapeutics stock for Q3 2019, down 69% quarter-over-quarter.
- 4 funds opened new DiaMedica Therapeutics positions in Q3 2019 and 3 closed out, a net change of +1 holder.
- The largest DiaMedica Therapeutics buyer in Q3 2019 was Vanguard Group, an estimated $151K added.
- The largest DiaMedica Therapeutics seller in Q3 2019 was Wexford Capital, an estimated $1.01M sold.
Based on aggregated 13F filings for Q3 2019.